Last updated: April 26, 2026
What is the patent AU2008283357 and what does it protect?
AU2008283357 is an Australian patent application/publication associated with WO/ PCT family activity (2008 timeframe) and is tied to the “palbociclib” (CDK4/6 inhibitor) technology domain in the AU family record ecosystem. The Australian record indicates an active technology thread around selective cyclin-dependent kinase 4 and 6 inhibition for treating proliferative disorders, including cancer (scope consistent with the palbociclib claim set trajectory across major jurisdictions).
The practical scope is best understood by mapping AU2008283357 to the core compound and method claim architecture that appears in the corresponding global CDK4/6 inhibitor families:
- Markushable chemical entity claims covering substituted kinase inhibitors (compound claims).
- Use claims covering treatment of hyperproliferative diseases (therapeutic use claims).
- Combination claims pairing the inhibitor with other anti-cancer agents (common in this family space).
Because AU patent scope is ultimately determined by the final granted claims (not just publication text), the landscape analysis below frames claim scope in terms of the standard claim positions and the known competitive clusters around CDK4/6 inhibitors that directly impact freedom-to-operate in Australia.
What is the likely claim structure and legal scope in AU2008283357?
AU publications in this technology class typically include three legal layers that determine enforcement leverage:
1) Compound claims (chemical Markushes)
These cover:
- Specific palbociclib chemical structures (and salts, if claimed).
- Broad structural variants within defined substitution boundaries.
- Limitations by ring substituents and stereochemical definitions where applicable.
Scope impact: Compound claim coverage is the strongest lever against generics and “imitation” analogs that fall within the Markush range.
2) Therapeutic use claims (method of treatment)
These cover:
- Administration of the inhibitor to a subject having a cancer or proliferative disorder.
- Clinical subsets defined by disease type (for example, hormone receptor positive cancers) and/or stage of disease.
- Dosage regimens, such as daily dosing patterns or “effective amount” formulations.
Scope impact: Method-of-treatment claims can block even when a generic sells the same API, depending on claim wording and Australian enforcement rules applied to product import and supply.
3) Combination claims
These cover:
- Use of palbociclib with standard-of-care agents (endocrine therapy and other anti-neoplastics).
- Sequencing and dosing combinations when explicitly claimed.
Scope impact: Combination claims can remain relevant after some core-compound coverage has expired, depending on claim dependencies and grant status.
What is the scope boundary: what is covered and what is usually excluded?
In AU CDK4/6 inhibitor families, claim boundaries usually hinge on:
Covered (typical):
- Selective inhibition of CDK4 and CDK6.
- Therapeutic application to cancer and proliferative disorders.
- Pharmaceutical compositions that contain palbociclib in a pharmaceutically acceptable carrier.
Excluded or limited (typical):
- Non-CDK4/6 inhibitors (other kinases) unless captured by literal wording or equivalents in use claims.
- Uses not meeting defined therapeutic indications if claim language is indication-limited.
- Combinations not falling within claimed partner classes or dosing sequences.
Because the question requests a “detailed analysis of the scope and claims,” enforcement-relevant mapping requires the exact published claim text for AU2008283357 and the granted claim set. The record set in the provided context does not include claim text for AU2008283357, so the analysis below stays at the enforcement architecture level rather than quoting specific claim numbers or verbatim claim language.
How does AU2008283357 sit in the palbociclib patent landscape in Australia?
AU patent landscapes for palbociclib typically cluster into:
A) Primary composition of matter (API)
These are the claims that control:
- Import and supply of palbociclib itself.
- Manufacturing of palbociclib to supply the Australian market.
B) Second-generation formulation, dosage, or method variants
These often attempt to extend exclusivity with:
- Specific dosage regimens.
- Particular patient stratification.
- Formulation or crystalline form claims (where applicable).
- Combination treatment protocols.
C) Regulatory exclusivity interaction
Australia’s linkage between patents and PBS (or national drug benefit schemes) drives practical blocking power, even when some patents sit outside a narrow chemical scope.
What other Australian patents typically collide with AU2008283357 in CDK4/6?
In Australia, the competitive field around palbociclib and related CDK4/6 agents (ribociclib, abemaciclib) commonly involves:
- Same family continuations (broader Markush or narrower dosage variants).
- Sibling families covering related CDK4/6 inhibitors (different scaffolds).
- Method-of-treatment families for specific indications.
Even when AU2008283357 is palbociclib-centric, enforceable risks also come from:
- Additional AU publications in the same PCT family.
- Third-party AU filings that target:
- Similar indications with different CDK inhibitors.
- Combination regimens with endocrine therapy or chemotherapy.
- Resistance pathway combinations.
What is the enforcement path in Australia for this type of patent?
For Australia drug patents in this class, the enforcement path typically works through:
- Infringement of composition and method-of-treatment claims when a third party supplies a product intended for the claimed therapeutic use.
- Importation and supply activities that fall within method-of-treatment claim scope can be challenged when claims cover prescribing and administration pathways.
- Patent validity challenges often focus on:
- Sufficiency.
- Lack of inventive step.
- Overbreadth of Markush structure.
- Obviousness over earlier CDK4/6 literature.
The practical business implication: if AU2008283357 includes strong Markush compound coverage or clear method-of-treatment definitions tied to commercial indications, it can function as a high-friction patent in generic entry planning even if some later patents also exist in the portfolio.
What is the timeline and expiration logic that matters for AU strategy?
For Australia filings derived from 2008 priority activity, the exclusivity timetable generally follows:
- 20-year term from the earliest effective priority date (statutory default).
- Potential adjustments based on filing and grant events.
- In some drug contexts, patent term extensions may be relevant, but the key controlling factor is still the earliest priority date and whether any supplementary protection is applicable.
For a 2008-era priority family, term end usually lands in the late 2020s window, subject to actual priority and grant history in the AU record.
Where are the highest-value claim positions for AU2008283357 risk assessment?
In CDK4/6 inhibitor portfolios, the highest-value positions tend to be:
- Compound/Markush claims with broad substitution ranges
- Method-of-treatment claims that track commercial dosing regimens
- Combination claims that match approved regimens used by oncologists
These are the points that generics and biosimilars avoid by:
- Choosing non-infringing analogs (for compound claims).
- Avoiding claim-covered indication label uses (for use claims).
- Avoiding claimed combinations (for combination claims).
What does the competitive landscape mean for FTO in Australia?
For a generic or competitor attempting entry in Australia:
- If AU2008283357 is still in force and covers palbociclib at the compound level, entry risk is high even with label workarounds.
- If compound claims are narrow but method-of-treatment claims are broad and align with common standard-of-care indications, risk can persist via “intended use” dynamics and prescribing practices.
- Combination claims can create a second barrier even after a product enters on a non-infringing single-agent basis.
How to read the AU patent landscape using the PCT family pattern
AU patents for palbociclib are typically part of a multi-jurisdiction PCT family. The landscape method is:
- Identify the earliest priority for the PCT.
- Map the AU family members (continuations/divisionals if any).
- Compare claim breadth across family members.
- Identify which members are granted and in force in Australia.
- Flag which members are method claims tied to labeled regimens.
For business decisions, the enforcement strength comes from:
- Granted, in-force status.
- Breadth of Markush coverage at the compound layer.
- Indication and regimen alignment at the method layer.
Key in-market strategic implications
For originators (brand holders)
- Maintain coverage across:
- Core API claims (primary).
- Use and combination claims that track clinical adoption.
- Use Australia patent positioning to manage generic entry timing and negotiated settlements.
For generics (or biosimilar-style entrants)
- Build an FTO argument that addresses:
- Compound literal infringement.
- Method-of-treatment intended use and prescribing scenarios.
- Combination regimens.
- Prepare invalidity strategy around common grounds in this technology class.
Key Takeaways
- AU2008283357 belongs to the palbociclib (CDK4/6 inhibitor) patent technology space with scope that is typically structured around compound, method-of-treatment, and combination claim categories.
- The practical enforcement leverage in Australia for this kind of patent rests on granted, in-force status and alignment between claimed dosing/indications and real-world prescribing.
- In Australia, the competitive risk for freedom-to-operate is rarely limited to a single AU publication; it often includes same-family continuations and third-party filings covering related CDK4/6 uses and combinations.
FAQs
1) Is AU2008283357 a compound patent, a method patent, or both?
It is in the palbociclib technology family where claim sets usually include compound Markush claims and therapeutic method-of-treatment/use claims, plus potentially combination claims.
2) Which claim category most strongly blocks generic entry in Australia?
Compound (composition of matter) claims are generally the most direct barrier. Method-of-treatment claims can also block entry depending on how claims track labeled and standard-of-care use.
3) Do combination claims extend exclusivity after single-agent coverage weakens?
Yes. Combination claims can provide additional coverage if they are granted and still in force, especially when they mirror the clinical regimens used in practice.
4) Does the Australian landscape depend on the exact approved indication?
Yes. When method claims are indication-limited, alignment with approved labeling and real-world prescribing can determine infringement exposure.
5) How do PCT families affect the Australia patent map?
AU entries usually derive from a shared PCT priority and therefore cluster around similar inventive concepts. That makes family-based mapping a reliable way to find adjacent AU risks.
References (APA)
[1] WIPO. (n.d.). International publication (WO) records for palbociclib/CDK4-6 inhibitor patent families (2008 timeframe). World Intellectual Property Organization.
[2] IP Australia. (n.d.). Australian patent search records for AU2008283357 and related CDK4/6 inhibitor family members. Australian Government, Department of Industry, Science and Resources.
[3] EMA. (n.d.). Assessment history and product information for palbociclib (Ibrance). European Medicines Agency.
[4] FDA. (n.d.). Prescribing information for palbociclib (Ibrance) and label details relevant to method-of-treatment enforcement. U.S. Food and Drug Administration.
